

Gerard SociÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3408017/publications.pdf>

Version: 2024-02-01

293
papers

23,895
citations

13087

68
h-index

8156

148
g-index

299
all docs

299
docs citations

299
times ranked

15570
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	0.6	13
2	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	1.3	9
3	Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation. <i>American Journal of Hematology</i> , 2022, 97, 274-282.	2.0	3
4	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	1.3	16
5	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 1068-1080.	1.3	7
6	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	1.3	4
7	Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. <i>Science Translational Medicine</i> , 2022, 14, eabg3083.	5.8	5
8	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	1.3	2
9	The EHA Research Roadmap: Hematopoietic Stem Cells and Allogeneic Transplantation. <i>HemaSphere</i> , 2022, 6, e0714.	1.2	1
10	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	1.3	3
11	Incidence, risk factors and outcome of BK virus hemorrhagic cystitis following allogeneic hematopoietic cell transplantation: a retrospective cohort study. <i>Bone Marrow Transplantation</i> , 2022, 57, 1287-1294.	1.3	6
12	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	1.3	7
13	A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2022, 198, 729-739.	1.2	4
14	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	1.7	14
15	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	1.3	1
16	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	1.3	9
17	FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study. <i>Bone Marrow Transplantation</i> , 2021, 56, 285-288.	1.3	5
18	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. <i>Leukemia</i> , 2021, 35, 225-228.	3.3	9

#	ARTICLE	IF	CITATIONS
19	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 622-634.	1.3	9
20	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1077-1085.	1.3	4
21	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Medicine, 2021, 10, 23-33.	1.3	7
22	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 171.e1-171.e8.	0.6	9
23	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1047-1055.	1.3	2
24	Postâ€transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLAâ€identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 209-218.	2.0	26
25	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 461-469.	1.3	2
26	Total body irradiation + fludarabine compared to busulfan + fludarabine as â€reduced-toxicity conditioningâ€for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 481-491.	1.3	10
27	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 193-197.e2.	0.3	4
28	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantâ€measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242.	3.3	6
29	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	0.6	24
30	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplantation, 2021, 56, 1888-1899.	1.3	18
31	Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of <i>ASXL1</i> mutations: a FIM study. Blood Advances, 2021, 5, 1442-1451.	2.5	48
32	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer Journal, 2021, 11, 88.	2.8	14
33	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/â€Cell lymphoma, nasal type: A French study from the SociÁ©tÁ© Francophone de Greffe de Moelle et de ThÁ©rapie Cellulaire (<sc>SFGMâ€TC</sc>). American Journal of Hematology, 2021, 96, 834-845.	2.0	5
34	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. Journal of Clinical Investigation, 2021, 131, .	3.9	16
35	Indole derivatives, microbiome and graft versus host disease. Current Opinion in Immunology, 2021, 70, 40-47.	2.4	14
36	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 2742-2748.	1.3	5

#	ARTICLE	IF	CITATIONS
37	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 545-557.	0.6	72
38	Secondary malignancies after transplantation for aplastic anemia. Bone Marrow Transplantation, 2021, 56, 2324-2325.	1.3	0
39	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	0.6	21
40	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	0.6	29
41	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transplantation and Cellular Therapy, 2021, 27, 817-835.	0.6	62
42	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. Bone Marrow Transplantation, 2021, 56, 3084-3087.	1.3	2
43	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 602-602.	0.6	1
44	Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party. Blood, 2021, 138, 1809-1809.	0.6	0
45	Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1. Blood, 2021, 138, 2901-2901.	0.6	0
46	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. Blood, 2021, 138, 2920-2920.	0.6	1
47	Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT. Blood, 2021, 138, 3890-3890.	0.6	0
48	In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4 ⁺ T _H 1 cell response. Science Immunology, 2021, 6, eabe8219.	5.6	32
49	Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans. British Journal of Dermatology, 2020, 182, 1038-1041.	1.4	7
50	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia, 2020, 34, 283-292.	3.3	48
51	A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplantation, 2020, 55, 86-92.	1.3	9
52	Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 982-986.	1.3	25
53	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia, 2020, 34, 87-99.	3.3	25
54	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. Bone Marrow Transplantation, 2020, 55, 110-116.	1.3	15

#	ARTICLE	IF	CITATIONS
55	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 633-640.	1.3	5
56	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	3.3	12
57	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 188, 428-437.	1.2	12
58	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
59	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 282-294.	2.0	7
60	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1050-1058.	1.3	42
61	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1642-1646.	1.3	4
62	Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 659-664.	2.0	7
63	Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2020, 126, 1004-1015.	2.0	14
64	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. <i>Frontiers in Immunology</i> , 2020, 11, 1537.	2.2	2
65	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2115-2120.	2.0	4
66	The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 3789-3794.	2.5	31
67	Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. <i>Blood Advances</i> , 2020, 4, 3927-3942.	2.5	16
68	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	0.6	34
69	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096613.	1.1	24
70	Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. <i>Blood</i> , 2020, 135, 227-229.	0.6	20
71	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1560-1569.	1.3	16
72	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39

#	ARTICLE	IF	CITATIONS
73	Human-Derived Î±1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1620-1626.	2.0	10
74	Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome. <i>Annals of Hematology</i> , 2020, 99, 2459-2461.	0.8	0
75	Cytogenetic risk score maintains its prognostic significance in <scp>AML</scp> patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1135-1141.	2.0	6
76	Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score. <i>Bone Marrow Transplantation</i> , 2020, 55, 1966-1974.	1.3	12
77	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	2.8	40
78	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	0.8	1
79	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
80	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
81	Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 992-997.	2.0	6
82	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	1.7	34
83	Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. <i>Blood Advances</i> , 2020, 4, 1824-1832.	2.5	54
84	Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e791-e793.	1.3	3
85	Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. <i>Bone Marrow Transplantation</i> , 2020, 55, 1367-1378.	1.3	9
86	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	3.3	30
87	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	1.3	97
88	The virome in hematologyâ€”Stem cell transplantation and beyond. <i>Seminars in Hematology</i> , 2020, 57, 19-25.	1.8	4
89	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 9-9.	0.6	0
90	Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study. <i>Blood</i> , 2020, 136, 40-42.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
92	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019, 33, 508-517.	3.3	45
93	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
94	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2490-2500.	2.0	9
95	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
96	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 108.	6.9	51
97	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	1.7	12
98	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1798-1802.	2.0	16
99	Guidelines for Secondary Solid Cancers Among HSCT Recipientsâ€”In Reply. <i>JAMA Oncology</i> , 2019, 5, 1064.	3.4	0
100	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1944-1952.	3.3	23
101	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	1.7	46
102	Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. <i>British Journal of Haematology</i> , 2019, 185, 297-310.	1.2	148
103	Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies. <i>Haematologica</i> , 2019, 104, e360-e363.	1.7	38
104	Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2019, 54, 1586-1594.	1.3	30
105	Viromewide antibody responses after transplantation. <i>Blood</i> , 2019, 134, 493-495.	0.6	0
106	Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. <i>Blood Advances</i> , 2019, 3, 184-186.	2.5	12
107	Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. <i>Blood Advances</i> , 2019, 3, 2424-2435.	2.5	66
108	Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. <i>Blood Advances</i> , 2019, 3, 2218-2229.	2.5	38

#	ARTICLE	IF	CITATIONS
109	Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. <i>Nature Communications</i> , 2019, 10, 5695.	5.8	91
110	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	3.4	33
111	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an <sc>ALWP</sc>/<sc>EBMT</sc> analysis. <i>Journal of Internal Medicine</i> , 2019, 285, 407-418.	2.7	35
112	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study. <i>Blood</i> , 2019, 134, 320-320.	0.6	3
113	Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study. <i>Blood</i> , 2019, 134, 1218-1218.	0.6	3
114	Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 4548-4548.	0.6	0
115	CD34+ Cell Dose Effects on Clinical Outcomes of Patients with Acute Myeloid Leukemia after T-Replete Haploidentical Allogeneic Hematopoietic Stemcell Transplantation Using Peripheral Blood Stem Cells. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 4586-4586.	0.6	0
116	Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Unrelated Cord Blood in Patients with T-Cell Non-Hodgkin Lymphoma : A Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGMC-TC). <i>Blood</i> , 2019, 134, 4596-4596.	0.6	0
117	Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report. <i>Blood</i> , 2019, 134, 2498-2498.	0.6	0
118	Association of Donor-Recipient HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem Cell Transplantation: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 3281-3281.	0.6	0
119	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	2.0	30
120	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018, 96, 73-81.	1.3	40
121	Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1295-1303.	1.3	17
122	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	2.0	21
123	Antiâ€thymocyte globulin improves survival free from relapse and graftâ€versusâ€host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphiaâ€negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the <sc>EBMT</sc>. <i>Cancer</i> , 2018, 124, 2523-2533.	2.0	18
124	Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. <i>European Respiratory Journal</i> , 2018, 51, 1702617.	3.1	71
125	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
126	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. <i>Haematologica</i> , 2018, 103, e103-e105.	1.7	16

#	ARTICLE	IF	CITATIONS
127	Allogeneic stem cell transplantation benefits for patients \geq 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	1.7	18
128	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 751-757.	2.0	39
129	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	1.3	37
130	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	0.6	43
131	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. <i>Journal of Internal Medicine</i> , 2018, 283, 166-177.	2.7	10
132	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	1.7	62
133	Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. <i>Bone Marrow Transplantation</i> , 2018, 53, 105-107.	1.3	9
134	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. <i>British Journal of Haematology</i> , 2018, 183, 766-774.	1.2	11
135	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 515-526.	0.4	25
136	Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. <i>Blood</i> , 2018, 132, 750-754.	0.6	44
137	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	2.0	40
138	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2523-2531.	2.0	19
139	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 1142-1152.	2.0	91
140	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 1317-1328.	1.7	84
141	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018, 9, 3379-3393.	0.8	40
142	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	1.3	31
143	<i>DUTPase</i> (<i>DUT</i>) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure. <i>Diabetes</i> , 2017, 66, 1086-1096.	0.3	22
144	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , 2017, 54, 12-16.	0.4	2

#	ARTICLE	IF	CITATIONS
145	Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the soci©t© Francophone de greffe de moelle et de th©rapie cellulaire (SFGM-TC). Bone Marrow Transplantation, 2017, 52, 678-682.	1.3	22
146	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology and Oncology, 2017, 10, 20.	6.9	43
147	Thiotepa©based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched©pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2017, 92, 997-1003.	2.0	34
148	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia© A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 667-675.e2.	0.2	12
149	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 139-149.	1.7	88
150	Anti-thymocyte globulin as graft- <i>versus</i> -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 224-234.	1.7	108
151	A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 2017, 129, 643-649.	0.6	58
152	Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD. Scientific Reports, 2017, 7, 10479.	1.6	16
153	The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. Nature Medicine, 2017, 23, 1080-1085.	15.2	109
154	Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Soci©t© Fran©aise de Greffe de Moelle Osseuse et Th©rapie Cellulaire and Eurocord. Bone Marrow Transplantation, 2017, 52, 1428-1435.	1.3	16
155	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematology, the, 2017, 4, e293-e301.	2.2	83
156	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Advances, 2017, 1, 477-485.	2.5	76
157	Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications. Stem Cell Investigation, 2017, 4, 40-40.	1.3	21
158	Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant. Blood, 2017, 130, 851-851.	0.6	1
159	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2017, 130, 852-852.	0.6	0
160	RIC <i>versus</i> MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget, 2016, 7, 43027-43038.	0.8	40
161	Usefulness of daily surveillance blood cultures in allogeneic hematopoietic stem cell transplant recipients on steroids: a 1©year prospective study. Transplant Infectious Disease, 2016, 18, 504-511.	0.7	5
162	Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International <sc>PNH</sc> Registry. Internal Medicine Journal, 2016, 46, 1044-1053.	0.5	59

#	ARTICLE	IF	CITATIONS
163	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	1.7	12
164	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	1.7	35
165	Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. <i>Haematologica</i> , 2016, 101, e209-e212.	1.7	4
166	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1206-1211.	2.0	70
167	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 248-255.	1.7	19
168	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2016, 51, 1184-1190.	1.3	31
169	Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. <i>British Journal of Haematology</i> , 2016, 175, 191-207.	1.2	103
170	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <i>Haematologica</i> , 2016, 101, 884-890.	1.7	30
171	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	0.6	66
172	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e312-e315.	1.7	9
173	Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation. <i>Stem Cell Reports</i> , 2016, 6, 970-984.	2.3	88
174	Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1721-1724.	2.0	11
175	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	2.0	110
176	Response to antiviral therapy in hematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. <i>Clinical Microbiology and Infection</i> , 2016, 22, 289.e1-289.e7.	2.8	18
177	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 351-357.	1.3	68
178	Quantification of the Mutant CALR Allelic Burden by Digital PCR. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 68-74.	1.2	30
179	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	0.6	10
180	Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2016, 128, 4563-4563.	0.6	1

#	ARTICLE	IF	CITATIONS
181	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	0.6	1
182	Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial. <i>Blood</i> , 2016, 128, 65-65.	0.6	4
183	Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3428-3428.	0.6	0
184	Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT. <i>Blood</i> , 2016, 128, 4643-4643.	0.6	0
185	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	0.6	0
186	A Comparison of Fractionated Myeloablative Total Body Irradiation Schedules Combined with Chemotherapy As Conditioning for Allograft Bone Marrow Transplantation in Patients with Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 981-981.	0.6	0
187	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. <i>Blood</i> , 2016, 128, 2285-2285.	0.6	15
188	Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 512-512.	0.6	0
189	Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. <i>Blood</i> , 2016, 128, 3476-3476.	0.6	0
190	Single HLA Mismatch Unrelated Donor Allogeneic Stem Cell Transplantation in Caucasian Recipients: Outcomes in HLA-A, -B, -C, -DRB1 and -DQB1 Mismatch Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). <i>Blood</i> , 2016, 128, 3474-3474.	0.6	0
191	Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3441-3441.	0.6	0
192	Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2280-2280.	0.6	5
193	Evaluation of Infectious Complications after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Following Reduced-Intensity and Myeloablative Conditioning: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) Study. <i>Blood</i> , 2016, 128, 5758-5758.	0.6	0
194	Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 114-123.	1.7	42
195	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	0.6	93
196	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 683-689.	1.7	36
197	High Number of Memory T Cells Is Associated with Higher Risk of Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 569-574.	2.0	18
198	Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 445-453.	2.0	29

#	ARTICLE	IF	CITATIONS
199	Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone Marrow Transplantation, 2015, 50, 1445-1452.	1.3	14
200	GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 1246-1250.	2.0	7
201	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 2015, 29, 2062-2068.	3.3	455
202	HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia, 2015, 29, 1496-1501.	3.3	65
203	Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. International Journal of Infectious Diseases, 2015, 39, 1-6.	1.5	80
204	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. Biology of Blood and Marrow Transplantation, 2015, 21, 761-767.	2.0	195
205	Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2015, 50, 840-845.	1.3	73
206	CD24 ^{hi} CD27 ⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood, 2015, 125, 1830-1839.	0.6	144
207	Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica, 2015, 100, 696-702.	1.7	141
208	Epidermal Elafin Expression Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease. Journal of Investigative Dermatology, 2015, 135, 999-1006.	0.3	30
209	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
210	Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type. Biology of Blood and Marrow Transplantation, 2015, 21, 357-363.	2.0	41
211	Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 2015, 50, 253-258.	1.3	6
212	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia, 2015, 29, 51-57.	3.3	67
213	Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party. Blood, 2015, 126, 1210-1210.	0.6	4
214	A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplantation, 2014, 49, 376-381.	1.3	8
215	Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplantation, 2014, 49, 628-633.	1.3	19
216	Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplantation, 2014, 49, 361-365.	1.3	15

#	ARTICLE	IF	CITATIONS
217	Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, e199-e200.	1.7	31
218	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	1.7	25
219	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
220	Prophylaxis and treatment of GVHD: EBMTâ€™ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014, 49, 168-173.	1.3	252
221	Acute kidney injury in critically ill allo-HSCT recipients. <i>Bone Marrow Transplantation</i> , 2014, 49, 1121-1122.	1.3	22
222	Current issues in chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 374-384.	0.6	336
223	Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. <i>Leukemia</i> , 2014, 28, 2406-2410.	3.3	16
224	Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. <i>Respiratory Medicine</i> , 2014, 108, 1525-1533.	1.3	50
225	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
226	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 887-894.	1.3	23
227	Long-Term Immune Reconstitution and Infection Burden after Mismatched Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 507-517.	2.0	71
228	Disease severity in chronic graft-versus-host disease: doctors' gut feeling versus biostatistics?. <i>Haematologica</i> , 2014, 99, 1534-1536.	1.7	1
229	Outcome after Relapse or Progression Following First Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia. a Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies. <i>Blood</i> , 2014, 124, 2510-2510.	0.6	1
230	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 729-729.	0.6	6
231	Bortezomib As Salvage Treatment for Multiple Myeloma Relapsing after Allogeneic Haematopoietic Stem Cell Transplantation: Efficacy, Tolerance and Modulation of Graft Versus Host Disease: A Study of the French Society for Stem Cell Transplantation and Cell Therapies (SFGM-TC). <i>Blood</i> , 2014, 124, 3959-3959.	0.6	0
232	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 1669-1676.	0.8	69
233	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	1.2	320
234	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. <i>Blood</i> , 2013, 122, 4279-4286.	0.6	176

#	ARTICLE	IF	CITATIONS
235	Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. <i>Blood</i> , 2013, 122, 1802-1812.	0.6	64
236	CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2013, 122, 3359-3364.	0.6	202
237	Outcomes Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Congenital Neutropenia (SCN): Preliminary Results. <i>Blood</i> , 2013, 122, 3355-3355.	0.6	2
238	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 735-741.	0.8	251
239	Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. <i>Haematologica</i> , 2012, 97, 1142-1148.	1.7	167
240	Second Solid Tumors: Screening and Management Guidelines in Long-Term Survivors After Allogeneic Stem Cell Transplantation. <i>Seminars in Hematology</i> , 2012, 49, 4-9.	1.8	25
241	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. <i>Leukemia</i> , 2012, 26, 2462-2468.	3.3	170
242	Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 406-413.	2.0	91
243	IDO in Human Gut Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 150-155.	2.0	24
244	Subsequent Malignant Neoplasms after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S139-S150.	2.0	38
245	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
246	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	12.5	352
247	Acute and Chronic Skin Graft-versus-Host Disease – Pathophysiological Aspects. <i>Current Problems in Dermatology</i> , 2012, 43, 91-100.	0.8	5
248	Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2012, 120, 356-356.	0.6	4
249	Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2012, 120, 233-233.	0.6	1
250	Outcome of Aplastic Anemia in Children. A Survey On Behalf of the SAA and PDWP of the EBMT. <i>Blood</i> , 2012, 120, 643-643.	0.6	0
251	Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 78-85.	2.0	100
252	Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. <i>Blood</i> , 2011, 117, e161-e170.	0.6	156

#	ARTICLE	IF	CITATIONS
253	Chronic GVHD: B cells come of age. <i>Blood</i> , 2011, 117, 2086-2087.	0.6	25
254	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGMTC). <i>British Journal of Haematology</i> , 2011, 152, 331-339.	1.2	104
255	Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 2230-2239.	0.8	530
256	Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Leukemia</i> , 2010, 24, 1867-1874.	3.3	86
257	Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2010, 116, 4439-4443.	0.6	227
258	Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1611-1628.	2.0	226
259	Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2009, 44, 589-594.	1.3	11
260	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , 2009, 10, 855-864.	5.1	620
261	Solid cancers after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2009, 113, 1175-1183.	0.6	427
262	MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. <i>Blood</i> , 2009, 114, 5216-5224.	0.6	94
263	Acute graft-versus-host disease: from the bench to the bedside. <i>Blood</i> , 2009, 114, 4327-4336.	0.6	257
264	Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 142, 11-26.	1.2	122
265	Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. <i>Blood</i> , 2008, 111, 939-944.	0.6	125
266	Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. <i>Blood</i> , 2008, 112, 3099-3106.	0.6	313
267	SOCS3 Promoter Methylation Is Not Involved in Primitive Myelofibrosis Megakaryocytic Spontaneous Growth. <i>Blood</i> , 2008, 112, 3716-3716.	0.6	0
268	Initial Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe Acute Gvhd and Poor Long-Term Survival. <i>Blood</i> , 2008, 112, 1164-1164.	0.6	0
269	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as a Curative Therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period Oligocentric French Experience.. <i>Blood</i> , 2008, 112, 1756-1756.	0.6	0
270	Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. <i>Blood</i> , 2007, 110, 1397-1400.	0.6	260

#	ARTICLE	IF	CITATIONS
271	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2007, 110, 4123-4128.	0.6	481
272	Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. <i>Haematologica</i> , 2007, 92, 589-596.	1.7	95
273	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2006, 355, 1233-1243.	13.9	1,060
274	Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 641-649.	1.3	104
275	Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients: A Reappraisal of Indications for Organ Failure Supports. <i>Journal of Clinical Oncology</i> , 2006, 24, 643-649.	0.8	196
276	Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigenâ€“Identical Siblings Versus Human Leukocyte Antigenâ€“Allelicâ€“Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 5695-5702.	0.8	245
277	Double Cord Blood Transplantation for Patients with High Risk Hematological Diseases: Delayed Immune Recovery and High Incidence of Infections.. <i>Blood</i> , 2006, 108, 2923-2923.	0.6	6
278	Risk Factors Analysis of Outcomes of Related Cord Blood Transplantation in Children with Hematological Malignancies.. <i>Blood</i> , 2006, 108, 3014-3014.	0.6	0
279	Mycophenolate Mofetil (MMF) with or without Tracolimus (FK506) as a Second Line Treatment for Steroid-Resistant Acute Graft-Versus-Host Disease. The Experience of Saint Louis Hospital.. <i>Blood</i> , 2006, 108, 2892-2892.	0.6	0
280	Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. <i>Blood</i> , 2005, 105, 3802-3811.	0.6	285
281	Considerations for Adult Cancer Survivors. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 516-522.	0.9	19
282	Current issues in allogeneic stem cell transplantation. <i>Hematology</i> , 2005, 10, 63-63.	0.7	3
283	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
284	Alternative Donor Stem Cell Transplantation after Reduced Intensity Conditioning Regimen for Patients with Bone Marrow Failure.. <i>Blood</i> , 2005, 106, 2894-2894.	0.6	0
285	Long-term outcome of hepatitis C infection after bone marrow transplantation. <i>Blood</i> , 2004, 103, 1618-1624.	0.6	165
286	Long-term outcome after bone marrow transplantation for severe aplastic anemia. <i>Blood</i> , 2004, 103, 2490-2497.	0.6	192
287	Nonmalignant late effects after allogeneic stem cell transplantation. <i>Blood</i> , 2003, 101, 3373-3385.	0.6	381
288	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002, 100, 406-414.	0.6	503

#	ARTICLE	IF	CITATIONS
289	Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1999, 341, 14-21.	13.9	666
290	Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine, 1997, 336, 897-904.	13.9	914
291	Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation. Annals of Internal Medicine, 1997, 126, 184.	2.0	204
292	Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood, 1996, 87, 386-392.	0.6	359
293	Malignant Tumors Occurring after Treatment of Aplastic Anemia. New England Journal of Medicine, 1993, 329, 1152-1157.	13.9	445